AccuStem submits Medicare coverage application for MSC lung cancer test; enters Novitas review

Accustem Sciences Inc.

Submitted local coverage determination to Novitas Solutions for MSC test reimbursement.
Novitas confirmed application complete and valid; now in review queue for JL region (DC, DE, MD, NJ, PA).
MSC test analyzes 24 circulating microRNAs in plasma to classify lung nodule risk.
If approved, could reduce unnecessary biopsies for benign nodules and prioritize high-risk patients.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.